Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

Dong-A ST

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: DA-5211; Drug: DA-5211-R1 + DA-5211-R2

Study type: Interventional

Funder types: Industry

Identifiers

NCT05132049

DA5211_BE_I

Details and patient eligibility

About

Pharmacokinetics and safety Profiles after administration of DA-5211 and co-administration of DA-5211-R1 and DA-5211-R2 in healthy adult volunteers

Enrollment: 42 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers
• BMI between 18 and 30 kg/m2
• Body weight: Male≥50kg, Female≥45kg
• Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

Exclusion criteria

• Subjects with allergy or drug hypersensitivity
• Subjects with clinically significant medical history
• Subjects with history of drug abuse or addicted

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

42 participants in 2 patient groups

Sequence A

Experimental group

Treatment:

Drug: DA-5211-R1 + DA-5211-R2

Drug: DA-5211

Sequence B

Experimental group

Treatment:

Drug: DA-5211-R1 + DA-5211-R2

Drug: DA-5211